Lundbeck has released its report for the first three months of 2022, which reveals revenue and EBIT (earnings before interest and taxes) results that exceed the analyst consensus estimates.
Analysts had predicted an EBIT result of DKK 731m (USD 103.7m), which Lundbeck exceeded with a result of DKK 875m (USD 124m). Revenue was predicted to land at DKK 4.2bn (USD 600m) by analysts, but totaled DKK 4.4bn (USD 620m) for the period.
More from MedWatch
In 2015, Genmab partnered with relatively unknown biotech firm Biontech. Reflecting on how far Genmab has come since, CEO Jan van de Winkel is still confident that partnerships, rather than acquisitions, are the way forward. If it had acquired Biontech at the time, the CEO speculates Genmab may have put a stop to other activities – including the Covid-19 vaccine efforts that went on to save millions of lives. This and fairness are worth remembering as biotech firms are increasingly strapped for cash, van de Winkel reflects.